L'hospitalet De Llobregat

• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon … Recruiting
  2025-521880-10-00 9 2026-02-16 Metastatic castrate resistant prostate cancer (mCRPC)
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• Phase 2 Study of INCB123667 in Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Recruiting
  2025-521513-14-00 4 2026-02-10 Ovarian Cancer
• TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat … Recruiting
  2025-521873-15-00 9 2026-02-09 Metastatic hormone-sensitive prostate cancer
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has … Recruiting
  2025-521636-10-00 4 2026-02-04 Progressive Forms of Multiple Sclerosis (PMS)
• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis Recruiting
  2025-521295-60-00 1 2026-01-29 Sporadic Amyotrophic Lateral Sclerosis
• Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in … Recruiting
  2025-521627-78-00 5 2026-01-28 Neoplasms, Lung
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Metastatic Clear Cell Renal Cell Carcinoma
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder. Recruiting
  2025-522026-13-00 4 2026-01-12 Obsessive compulsive disorder
• To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan … Recruiting
  2025-521128-31-00 9 2025-12-18 Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting
  2024-517653-27-00 4 2025-12-17 Prostate Cancer
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• A study to investigate the safety and efficacy of ONA-255 in participants with advanced cancer Recruiting
  2025-522233-62-00 7 2025-12-12 Advanced cancer; breast cancer; metastatic gastric / gastroesophageal
• A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non … Recruiting
  2024-515125-28-00 4 2025-12-08 Non-obstructive hypertrophic cardiomyopathy
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Recruiting
  2025-521278-32-00 4 2025-12-04 Idiopathic Pulmonary Fibrosis (IPF)

Showing 193–216 of 1,017 trials